DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

ETFs are one of our favorite investment instruments. They provide exposure to a large swath of stocks, allowing you to ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...

These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns. The post 2 cheap shares that could be takeover targets in 2025 ...

EST Cathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics (CRSP) todayStay Ahead of the Market:Discover outperforming ...